Recently, findings from a Phase II clinical trial conducted in China for GZR4 injection, a Class 1 innovative once‑weekly basal insulin independently developed by Ganli Pharmaceutical, have been officially published in Metabolism‑Clinical and Experimental (commonly referred to as Metabolism), a prestigious international journal in endocrinology. As a globally recognized top academic journal in endocrinology and […]